WHO ICTRP trial
Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in…
EUCTR2016-001429-16-FR · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2016-001429-16-FR |
|---|---|
| Public title | Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression. |
| Scientific title | Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression. |
| Primary sponsor | HORAMA SA |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France |
| Conditions | Retinitis Pigmentosa;Therapeutic area: Diseases [C] - Eye Diseases [C11] |
| Interventions | Product Code: HORA-PDE6B (AAV2/5.hPDE6B) Pharmaceutical Form: Solution for injection |
| Registration date | Dec 9, 2017 |
| Secondary IDs | HORA-PDE6B-001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: